Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Prostate Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 53 articles: HTML format

Single Articles

March 2026
1. BREVI A, Lorenzoni M, Caputo S, Yamada Y, et al
   Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression.
   Cancer Res. 2026 Mar 5. doi: 10.1158/0008-5472.CAN-25-2704.
   PubMed     Abstract available
   
   
   
2. ALIZADEH-GHODSI M, Goldstein AS
   Polyamine Metabolism as a Metabolic Vulnerability in Prostate Cancer Treated with Supraphysiological Androgens.
   Cancer Res. 2026;86:1095-1097.
   PubMed     Abstract available
   
   
   February 2026
3. THIENGER P, Akhoundova D, Rubin MA
   Reversing-or Rewiring-Lineage Plasticity? Lessons from EZH2 Loss in Prostate Cancer.
   Cancer Res. 2026;86:827-829.
   PubMed     Abstract available
   
   
   
4. MONTEAGUDO-GARCIA O, Nombela P, Roman AC, Fernandez-Rodero V, et al
   ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation.
   Cancer Res. 2026;86:622-641.
   PubMed     Abstract available
   
   
   January 2026
5. THIENGER P, Paassen I, Yao X, Rubin PD, et al
   A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader Molecules.
   Cancer Res. 2026 Jan 14. doi: 10.1158/0008-5472.CAN-25-2928.
   PubMed     Abstract available
   
   
   
6. GULLA S, Sharma T, Gardner E, Li C, et al
   MECOM Function is Critical for AR-Driven Treatment-Resistant Prostate Cancer.
   Cancer Res. 2026 Jan 13. doi: 10.1158/0008-5472.CAN-25-1720.
   PubMed     Abstract available
   
   
   December 2025
7. KITTANE S, Ladewig E, Li T, Love JR, et al
   The Histone Methyltransferase KMT2D is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration Resistant Prostate Cancer.
   Cancer Res. 2025 Dec 11. doi: 10.1158/0008-5472.CAN-25-2053.
   PubMed     Abstract available
   
   
   November 2025
8. KUMAR R, Jonnatan S, Sanin DE, Vakkala V, et al
   Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer.
   Cancer Res. 2025 Nov 21. doi: 10.1158/0008-5472.CAN-25-1532.
   PubMed     Abstract available
   
   
   
9. JACOBI JJ, Wadosky KM, Jaiswal N, Zhang X, et al
   EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression.
   Cancer Res. 2025 Nov 12. doi: 10.1158/0008-5472.CAN-25-2747.
   PubMed     Abstract available
   
   
   
10. ANZULES JM, Sayegh M, Li YR
    Exploiting AR-Synergistic Metabolic Vulnerabilities in Prostate Cancer.
    Cancer Res. 2025;85:4045-4046.
    PubMed     Abstract available
    
    
    
11. MARSILIO L, Barrios S, Maksimovic S, Maccarini A, et al
    In Silico Digital Twins of Bone Metastasis Enable Investigation of Tumor Progression and Therapy Response.
    Cancer Res. 2025;85:4269-4284.
    PubMed     Abstract available
    
    
    October 2025
12. NASR MM, Wadie B, Li T, Frieling JS, et al
    PRDM16 Regulates Prostate Cancer Cell Dormancy and Prevents Bone Metastatic Outgrowth.
    Cancer Res. 2025 Oct 17. doi: 10.1158/0008-5472.CAN-24-4809.
    PubMed     Abstract available
    
    
    
13. ALHOURANI F, Tauziet M, Ayeul M, Dambrun P, et al
    Targeting SUV4-20H Epigenetic Enzymes Enhances Topoisomerase II Poisoning in Prostate Cancer.
    Cancer Res. 2025 Oct 1. doi: 10.1158/0008-5472.CAN-24-3974.
    PubMed     Abstract available
    
    
    September 2025
14. LIU S, Hsu EC, Aslan M, Garcia-Marques F, et al
    Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis.
    Cancer Res. 2025 Sep 5. doi: 10.1158/0008-5472.CAN-24-4855.
    PubMed     Abstract available
    
    
    
15. MURPHY KC, DeMarco KD, Zhou L, Peura J, et al
    MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T Cell and Immunotherapy Responses in Prostate Cancer.
    Cancer Res. 2025 Sep 3. doi: 10.1158/0008-5472.CAN-25-2532.
    PubMed     Abstract available
    
    
    
16. JIANG J, Liu S, Xu C, He L, et al
    LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer.
    Cancer Res. 2025 Sep 3. doi: 10.1158/0008-5472.CAN-25-0587.
    PubMed     Abstract available
    
    
    August 2025
17. GUO X, Zhong J, Qian J, Pan X, et al
    tRF-21LeuTAA Promotes Oxidative Stress by Altering Glutathione Metabolic Enzymes to Support Prostate Cancer Progression.
    Cancer Res. 2025 Aug 29. doi: 10.1158/0008-5472.CAN-25-0273.
    PubMed     Abstract available
    
    
    
18. DAI Y, Liu L, Luo Y, Zhang C, et al
    Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation.
    Cancer Res. 2025 Aug 27. doi: 10.1158/0008-5472.CAN-24-4247.
    PubMed     Abstract available
    
    
    
19. VENKADAKRISHNAN VB, Presser A, Voss NCE, Neiswender J, et al
    Epigenetic De-repression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression.
    Cancer Res. 2025 Aug 21. doi: 10.1158/0008-5472.CAN-25-0636.
    PubMed     Abstract available
    
    
    
20. HOSSEINI N, Mannan R, Rebernick RJ, Su F, et al
    Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration Resistant Prostate Cancer.
    Cancer Res. 2025 Aug 18. doi: 10.1158/0008-5472.CAN-24-3687.
    PubMed     Abstract available
    
    
    
21. CORDOVA RA, Elbanna M, Rupert C, Orsi SA, et al
    Caloric Restriction Enhances the Efficacy of Anti-Androgen Therapy in Prostate Cancer by Inhibiting Androgen Receptor Translation.
    Cancer Res. 2025 Aug 8. doi: 10.1158/0008-5472.CAN-24-1986.
    PubMed     Abstract available
    
    
    
22. MA S, Ge Y, Lu Z, Zhang J, et al
    Integrated Omics and Multi-Cohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer.
    Cancer Res. 2025 Aug 4. doi: 10.1158/0008-5472.CAN-24-5018.
    PubMed     Abstract available
    
    
    July 2025
23. YE Q, Ma B, Li L, Wang Z, et al
    A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition.
    Cancer Res. 2025 Jul 29. doi: 10.1158/0008-5472.CAN-24-4096.
    PubMed     Abstract available
    
    
    
24. ZHANG J, Chen W, Zhang C, He Q, et al
    Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion.
    Cancer Res. 2025 Jul 23. doi: 10.1158/0008-5472.CAN-24-3748.
    PubMed     Abstract available
    
    
    April 2025
25. SMELIK M, Diaz-Roncero Gonzalez D, An X, Heer R, et al
    Combining Spatial Transcriptomics, Pseudotime, and Machine Learning Enables Discovery of Biomarkers for Prostate Cancer.
    Cancer Res. 2025 Apr 28. doi: 10.1158/0008-5472.CAN-25-0269.
    PubMed     Abstract available
    
    
    
26. CRUZ-HERNANDEZ CD, Smith B, Billet S, Thiruvalluvan M, et al
    A Cyanobacteria-derived RNA aptamer resensitizes prostate cancer to hormone therapy.
    Cancer Res. 2025 Apr 28. doi: 10.1158/0008-5472.CAN-24-4039.
    PubMed     Abstract available
    
    
    February 2025
27. ZHAO Y, Ramesh N, Xu P, Sei E, et al
    Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer During Serial Therapy.
    Cancer Res. 2025 Feb 24. doi: 10.1158/0008-5472.CAN-24-1943.
    PubMed     Abstract available
    
    
    
28. ZHANG C, Ding J, Lim KS, Zhou W, et al
    JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer.
    Cancer Res. 2025 Feb 4. doi: 10.1158/0008-5472.CAN-23-2796.
    PubMed     Abstract available
    
    
    December 2024
29. SIPOLA J, Munzur AD, Kwan EM, Seo CCY, et al
    Plasma cell-free DNA chromatin immunoprecipitation profiling depicts phenotypic and clinical heterogeneity in advanced prostate cancer.
    Cancer Res. 2024 Dec 9. doi: 10.1158/0008-5472.CAN-24-2052.
    PubMed     Abstract available
    
    
    November 2024
30. BAE TH, Sung KW, Pham TM, Najy AJ, et al
    An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate Cancer.
    Cancer Res. 2024 Nov 12. doi: 10.1158/0008-5472.CAN-24-0591.
    PubMed     Abstract available
    
    
    
31. MCQUILLEN CN, Brady NJ
    ASCL1 Drives the Development of Neuroendocrine Prostate Cancer.
    Cancer Res. 2024;84:3499-3501.
    PubMed     Abstract available
    
    
    October 2024
32. ZHANG L, Troccoli CI, Mateo-Victoriano B, Misiara Lincheta L, et al
    Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer.
    Cancer Res. 2024 Oct 10. doi: 10.1158/0008-5472.CAN-24-0133.
    PubMed     Abstract available
    
    
    September 2024
33. RODARTE KE, Nir Heyman S, Guo L, Flores L, et al
    Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1.
    Cancer Res. 2024 Sep 12. doi: 10.1158/0008-5472.CAN-24-1388.
    PubMed     Abstract available
    
    
    August 2024
34. SONG H, Lu T, Han D, Zhang J, et al
    YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer.
    Cancer Res. 2024 Aug 13. doi: 10.1158/0008-5472.CAN-24-0932.
    PubMed     Abstract available
    
    
    
35. NING S, Armstrong CM, Xing E, Leslie AR, et al
    LX1 Targets Androgen Receptor Variants and AKR1C3 to overcome Therapy Resistance in Advanced Prostate Cancer.
    Cancer Res. 2024 Aug 1. doi: 10.1158/0008-5472.CAN-24-0440.
    PubMed     Abstract available
    
    
    July 2024
36. SHRESTHA R, Chesner LN, Zhang M, Zhou S, et al
    An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression.
    Cancer Res. 2024 Jul 11. doi: 10.1158/0008-5472.CAN-24-0890.
    PubMed     Abstract available
    
    
    
37. YOO YA, Quan S, Yang W, Guo Q, et al
    Asparagine Dependency is a Targetable Metabolic Vulnerability in TP53-Altered Castration-Resistant Prostate Cancer.
    Cancer Res. 2024 Jul 3. doi: 10.1158/0008-5472.CAN-23-2910.
    PubMed     Abstract available
    
    
    June 2024
38. ZHANG W, Maeser D, Lee A, Huang Y, et al
    Integration of Pan-Cancer Cell Line and Single-Cell Transcriptomic Profiles Enables Inference of Therapeutic Vulnerabilities in Heterogeneous Tumors.
    Cancer Res. 2024;84:2021-2033.
    PubMed     Abstract available
    
    
    
39. LI W, Guo F, Zeng R, Liang H, et al
    CDK4/6 Alters TBK1 Phosphorylation to Inhibit the STING Signaling Pathway in Prostate Cancer.
    Cancer Res. 2024 Jun 11. doi: 10.1158/0008-5472.CAN-23-3704.
    PubMed     Abstract available
    
    
    
40. BOUFAIED N, Chetta P, Hallal T, Cacciatore S, et al
    Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer.
    Cancer Res. 2024;84:1834-1855.
    PubMed     Abstract available
    
    
    
41. FRIGO DE
    Diet and Tumor Genetics Conspire to Promote Prostate Cancer Metabolism and Shape the Tumor Microenvironment.
    Cancer Res. 2024;84:1742-1744.
    PubMed     Abstract available
    
    
    
42. GALLAGHER K, Strobl MAR, Park DS, Spoendlin FC, et al
    Mathematical Model-Driven Deep Learning Enables Personalized Adaptive Therapy.
    Cancer Res. 2024;84:1929-1941.
    PubMed     Abstract available
    
    
    April 2024
43. SHRESTHA RK, Nassar ZD, Hanson AR, Iggo R, et al
    ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis.
    Cancer Res. 2024 Apr 24. doi: 10.1158/0008-5472.CAN-23-1489.
    PubMed     Abstract available
    
    
    
44. CUNNINGHAM M, Schiewer MJ
    PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer.
    Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-3458.
    PubMed     Abstract available
    
    
    
45. MURPHY S, Rahmy S, Gan D, Liu G, et al
    Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy.
    Cancer Res. 2024 Apr 8. doi: 10.1158/0008-5472.CAN-23-2742.
    PubMed     Abstract available
    
    
    March 2024
46. SHU F, Liu H, Chen X, Liu Y, et al
    m6A modification promotes EMT and metastasis of castration-resistant prostate cancer by upregulating NFIB.
    Cancer Res. 2024 Mar 27. doi: 10.1158/0008-5472.CAN-23-1954.
    PubMed     Abstract available
    
    
    January 2024
47. ZHAO J, Xu N, Zhu S, Nie L, et al
    Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate.
    Cancer Res. 2024;84:154-167.
    PubMed     Abstract available
    
    
    December 2023
48. MISHRA R, Blinka S, Hsieh AC
    Citron Kinase Is a Druggable Target in Treatment-Resistant Prostate Cancer.
    Cancer Res. 2023;83:4008-4009.
    PubMed     Abstract available
    
    
    
49. AWAD D, Cao PHA, Pulliam TL, Spradlin M, et al
    Adipose triglyceride lipase is a therapeutic target in advanced prostate cancer that promotes metabolic plasticity.
    Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-0555.
    PubMed     Abstract available
    
    
    October 2023
50. GARCIA-RODRIGUEZ JL, Korsgaard U, Ahmadov U, Jarlstad Olesen MT, et al
    Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells.
    Cancer Res. 2023;83:3340-3353.
    PubMed     Abstract available
    
    
    
51. RAWAT C, Ben-Salem S, Singh N, Chauhan G, et al
    Prostate cancer progression relies on the mitotic kinase citron kinase.
    Cancer Res. 2023 Oct 6. doi: 10.1158/0008-5472.CAN-23-0883.
    PubMed     Abstract available
    
    
    September 2023
52. LI Z, Ning K, Zhao D, Zhou Z, et al
    Targeting the metabolic enzyme PGAM2 overcomes enzalutamide resistance in castration-resistant prostate cancer by inhibiting BCL2 signaling.
    Cancer Res. 2023 Sep 7. doi: 10.1158/0008-5472.CAN-23-0308.
    PubMed     Abstract available
    
    
    
53. NYQUIST MD, Coleman IM, Lucas JM, Li D, et al
    Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
    Cancer Res. 2023;83:2938-2951.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum